Oncologists Explore Treatment Options in LGSOC, Look Toward Promising Future

Although there are no FDA-approved treatments specifically indicated for low-grade serous ovarian cancer, therapeutic options for these patients are rapidly expanding, with promising new approaches progressing through clinical development.

Related Keywords

Missouri ,United States ,Texas ,Houston ,Washington University ,Corrs ,Davidm Omalley ,Premalh Thaker ,Shannonn Westin , ,Onclive News Network ,Department Of Obstetrics ,Division Of Gynecologic Oncology ,Ohio State University College Of Medicine ,University Of Texas Md Anderson Cancer Center ,Ohio State University Comprehensive Cancer Center ,Department Of Gynecologic Oncology ,Division Of Surgery ,Emerging Therapies ,Low Grade Serous Ovarian Cancer ,Gynecologic Oncology ,Reproductive Medicine ,Cancer Center ,Lynn Mutch Professor ,Washington University School ,Ohio State University College ,Ovarian Cancer ,Lgsoc ,Gynecologic Cancer ,D ,Bph ,Iacog ,Md Anderson Cancer Center ,Chemotherapy ,Nrg Gy019 Trial ,Us ,University School Of Medicine ,Gog281 Logs Trial ,Asco Annual Meeting ,Ramp201 Study ,Avutometinib ,Defactinib ,Davidmo X27 Malley ,The Ohio State University College Of Medicine ,The Ohio State University Comprehensive Cancer Center James ,